Pathological Mechanism Study of Aerobic Exercise Regulating Cold Stress-induced Hypertension Via the Thermosensitive Target-mediated Sympathetic Nerve Pathway

This study focuses on the specificity of thermosensitive targets in populations with hypertension in cold regions, identifies core targets through transcriptome sequencing and clinical validation, and clarifies the regulatory mechanism of moderate-intensity aerobic exercise through a prospective cohort study, providing scientific basis for precise prevention and treatment of hypertension in cold regions and personalized exercise intervention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

60 year–69 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Harbin Sport University

Harbin, Heilongjiang, 150008, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Same as the inclusion criteria for cold region hypertensive patients in the first stage; No regular moderate-intensity aerobic exercise in the past 3 months (≥3 times per week, ≥30 minutes per session); Exercise risk assessment is low to moderate risk (negative PAR-Q+ questionnaire); Voluntarily participate in this study and sign informed consent.

Exclusion criteria

Same as the exclusion criteria in the first stage; Complicated with exercise contraindications (such as severe coronary heart disease, uncontrolled arrhythmia, severe osteoarthropathy, etc.); Unable to complete 16-week follow-up.

Treatment and study plan

Exercise exposure

Behavioral

Patients with essential hypertension in cold regions who met the inclusion criteria were prospectively recruited and divided into an exercise exposure group and a non-exercise control group based on their willingness to accept and adhere to the exercise protocol developed for this study, with a follow-up period of 16 weeks. At baseline and the end of follow-up, we measured the expression of core thermosensitive targets, blood pressure (BP), heart rate variability (HRV), as well as the levels of sympathetic neurotransmitters and indicators of the renin-angiotensin-aldosterone system (RAAS), and compared the changes in these indicators between the two groups.

Primary outcomes

blood pressure (BP)

Time frame: December 28, 2025

Systolic blood pressure, unit: mmHg Diastolic blood pressure, unit: mmHg Mean arterial pressure, unit: mmHg
heart rate variability (HRV)

Time frame: 28 December 2025

Low Frequency，Unit: nu High Frequency ，Unit: nu Low Frequency / High Frequency ratio Root Mean Square of Successive Differences，Unit: ms Percentage of successive NN intervals differing by more than 50 ms，Unit: % Standard Deviation of all Normal-to-Normal RR intervals，Unit: ms
markers of the sympathetic nervous system (SNS)

Time frame: December 28, 2025

Epinephrine, unit: ng/L Norepinephrine, unit: ng/L
mRNA expression of genes

Time frame: December 28, 2025

Unit: relative expression level

Sponsors and collaborators

Lead sponsor

Wang Jingfeng

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Jun 24, 2026
Registry last updated: Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed